Postby Oscar » Sat Nov 28, 2020 5:22 pm


[ ... PartId=0.1 ]

WADENA NEWS November 30, 2020 Page 4

On November 25, 2020, Scott Moe spent half his press briefing complaining about Trudeau not having a lab in Canada to produce a vaccine for COVID-19. Just a little refresher for Scott Moe, it was actually his friends who sold off Connaught Laboratories.

These birds of a feather are stuck together on their schemes to sell off the public good for corporate profit. Now that it’s come back to bite us yet again, I feel it’s my duty to remind Saskatchewanians the truth.

Canada’s National Vaccine Lab, which produced vaccines for polio and smallpox, was transferred to private ownership in 1986 by Prime Minister Brian Mulroney. This had the full support of Saskatchewan Premier Grant Devine, whose own privatization scheme is much more memorable: Saskatchewan’s PotashCorp.

Premier Brad Wall, from whom Moe inherited his present title, was working for Devine at that time. Maybe that will twig Scott Moe’s memory?

The Saskatchewan Green Party remembers, and we’ll continue to hold this government to account and fight for a better province for us all.

We must once and for all stop the privatization of our most vital public services, and moving forward, invest in Saskatchewan and invest in Canada. It’s time for leadership.

— Naomi Hunter, Leader,
Saskatchewan Green Party.
Site Admin
Posts: 8640
Joined: Wed May 03, 2006 3:23 pm


Postby Oscar » Sat Nov 28, 2020 5:36 pm

Fact-checking the arguments on the PM's vaccine record - What's really happened with government spending on immunization in the past eight years?

[ ... KsgubldhDk ]

By Genna Buck February 19, 2015

QUOTE: "On Tuesday, Trudeau slammed Stephen Harper for running “partisan government ads” instead of a public health campaign to encourage parents to vaccinate their children. Trudeau went on to accuse the government of cutting the Public Health Agency of Canada’s budget for immunization programs by 23 per cent since 2006-07. . . . . "

= = = =

Conservatives & Connaught Laboratories - Pg. 68 . . . .

[ ... M16453.PDF ]

= = = =


[ ]

Ownership transfer and privatization - Transfer to the Canada Development Corporation

In June 1972, the Connaught Medical Research Laboratories was sold to the Canada Development Corporation (CDC) for $25 million (Canadian Dollars) and became known as "Connaught Laboratories Limited".[73] Logistically, it was incorporated as "CDC Life Sciences Inc." under the CDC's healthcare division titled "ConnLab Holdings Ltd."[74][75][76] At the time the CDC, charged with developing and maintaining Canadian-controlled companies in the private sector through a mixture of public and private investment, was federally owned. Nonetheless, the sale continued to stir controversy in the following years as the Labs became profit-driven and became subject to governmental investigation under allegations of mismanagement and deteriorated manufacturing standards.[77] By 1974, Connaught had increased prices with one-day notice on most products, including insulin, such that one report noted that "some of its insulin wholesale prices became higher than the top U.S. retail prices found in a check just across the border at Niagara Falls." A more serious faux pas was noted in regard to an unannounced increase in the potency of a smallpox vaccine which caused strong reactions in patients and alarmed health authorities in Saskatchewan.[78] The following February, The Globe and Mail ran a series of articles inquiring into Connaught's activities under the CDC.[79] A separate review in 1989 reiterated that "staff was cut and plans were made to sell land and other assets to raise cash to cover financial mismanagement."[30]

Expansion into the United States

In 1978, Connaught expanded into the United States with the acquisition of a vaccine production facility in Swiftwater, Pennsylvania.[73][80] The expansion established "Connaught Laboratories Inc.", a U.S. subsidiary of Connaught Laboratories Ltd. The acquired facility was previously operated by Merrell-National Laboratories, the largest producer of swine flu vaccine in the U.S. Government's ill-fated mass immunization program in 1976 and the sole source of the yellow fever vaccine in the United States.[81]

The expansion consisted of a three-way deal between Connaught Laboratories Ltd., Richardson-Merrell Inc., and the Salk Institute for Biological Studies. The Salk Institute would take over the entirety of Richarson-Merrell's research and production plant as the company exited the market. Connaught would acquire the vaccine manufacturing facilities from the Salk Institute.[81]

Privatization and sale to Institut Mérieux

By 1984, government enterprise had become unfashionable under Brian Mulroney and the CDC was sold to the private sector.[82][83] Its holdings, including Connaught, were sold through two public issues in 1984 and in 1987.[30] As the shares were sold off, "CDC Life Sciences Inc." by which Connaught was renamed "Connaught Biosciences Inc." in 1988.[75]

In April 1988, Institut Mérieux of France tried to buy a controlling stake in Connaught, but was blocked by the Ontario and Quebec securities commissions because the acquisition favoured one group of shareholders over others. A year later on 7 March 1989, Institut Mérieux proposed a merger between Connaught and its drug division that would result in Mérieux owning 51% of the combined operations.[84][85][86] The move was rejected by shareholders.[87] In September 1989, Swiss-based Ciba-Geigy (now Novartis) and California-based Chiron Corporation made a joint offer of $30-a-share (US$764 million). Institut Mérieux made yet another bid for Connaught, topping the joint offer with a bid of $37-a-share (US$813 million).[88] In October, the Canadian government rejected the initial bid on the ground that the offer could not be judged as being of "net benefit" to Canada.[89] At this time, Connaught was the world's largest manufacturer of influenza vaccines but no longer manufactured insulin, instead "ironically ... selling insulin products made by Novo Nordisk Group of Denmark."[30][74][90]

Since the 1972 sale of the laboratories to the CDC stipulated that the drug firm could not be sold to a foreign-owned company, University of Toronto opposed the merger "on the ground that a foreign takeover would mean a loss of research spending and jobs in Canada."[91][92] It took Connaught to court seeking an injunction to block the sale, but withdrew its objection following an agreement with Mérieux that medical research support will continue if the company's bid succeeds.[93][94] The Canadian government approved the bid for Connaught in December 1989.[95] The move was criticized by many, including Jim Peterson, who was critical of Brian Mulroney's industrial policy and voiced that "no other industrialized country ... would permit the takeover of its leading biotechnology firm."[87]

Connaught was sold to Mérieux, and transformed into the North American component of Pasteur Mérieux Connaught (PMC) owned by Mérieux's parent company, Rhône-Poulenc.[87] Since ownership of Connaught had been transferred, "Connaught Biosciences Inc." was formally dissolved in 1990.[75] A decade later in 1999, Rhône-Poulenc merged with Hoechst of Germany to create Aventis. PMC thus became Aventis-Pasteur, a subsidiary of Aventis devoted to vaccines. In 2004, Aventis was acquired by Sanofi. Aventis-Pasteur, the vaccine subsidiary, became Sanofi Pasteur.[96][73]

Today, the Connaught Laboratories' facilities are known as the "Connaught Campus" of Sanofi Pasteur.[96]
Site Admin
Posts: 8640
Joined: Wed May 03, 2006 3:23 pm

Return to Health/MEDICARE

Who is online

Users browsing this forum: No registered users and 1 guest